secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-06-08T13:01:47+00:00
Accession:  0001104659-26-071211
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia DA-1726 48mg cohort achieves 9.1% weight loss at Day 54; vanoglipel combo shows synergy in MASH/T2D
--------------------------------------------------------------------------------

- DA-1726 Phase 1 48mg cohort: 9.1% mean weight loss at Day 54 (p<0.05 vs placebo), no plateau observed.
- Waist circumference reduced by 9.8 cm at Day 54; BMI reduced by 3.4 kg/m².
- Vanoglipel + resmetirom in MASH mouse model: 23.6% weight loss vs control, ALT reduction 83.5%.
- Vanoglipel + metformin in T2D model: 16.3% weight loss, 28.7% non-fasting glucose reduction.
- Phase 1 Part 3 titration studies for higher-dose DA-1726 ongoing; results expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/0001104659-26-071211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/mtva-20260608x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-071211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer